IP Library Granted Patent US 7,374,891
Granted Patent B2
US 7,374,891 · App. 11/005,843 · Granted May 20, 2008

Methods to identify compounds that modulate rage

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,374,891
App. No.
11/005,843
Granted
May 20, 2008
Kind
B2
Abstract

Provided are methods to detect of modulators of the Receptor for Advanced Glycated Endproducts (RAGE). The invention comprises a method for detection of RAGE modulators comprising: adsorbing a RAGE ligand onto a solid surface; adding a compound of interest and a protein comprising RAGE or fragment thereof, to the preadsorbed ligand; adding an antibody which binds to RAGE or fragment thereof and a secondary antibody which binds to the anti-RAGE antibody; measuring the secondary antibody bound to the anti-RAGE antibody; and comparing the amount of RAGE bound to the ligand in the presence of varying amounts of the compound of interest. In an embodiment, the fragment of RAGE is sRAGE. In one aspect, the invention use of compounds detected by the method for treatment of AGE-related syndromes including complications associated with diabetes, kidney failure, lupus nephritis or inflammatory lupus nephritis, amyloidoses, Alzheimer's disease, cancer, inflammation, and erectile dysfunction.

Claims (36)

1. A method for detection of RAGE ligands comprising:

adsorbing a RAGE ligand onto a solid surface;

adding a compound of interest and a protein comprising a RAGE fragment comprising the amino acid sequence SEQ ID NO: 3 to the preadsorbed ligand;

adding an anti-RAGE antibody which binds to said protein;

determining the amount of said protein bound to the ligand by measuring the amount of anti-RAGE antibody bound; and

comparing the amount of said protein bound to the ligand in the presence of varying amounts of the compound of interest.

2. The method of claim 1 , wherein the anti-RAGE antibody comprises a monoclonal antibody.

3. The method of claim 1 , wherein the anti-RAGE antibody comprises polyclonal antibody.

4. The method of claim 1 , further comprising adding a second antibody which recognizes the anti-RAGE antibody.

5. The method of claim 4 , wherein the anti-RAGE antibody and secondary antibody are allowed to complex prior to being added.

6. The method of claim 4 , further comprising performing a colorimetric assay for the secondary antibody.

7. The method of claim 1 , wherein the solid surface comprises a microtiter well.

8. The method of claim 1 , wherein the solid surface comprises a dip-stick.

9. The method of claim 1 , wherein the ligand comprises an advanced glycated endproduct, or fragment thereof.

10. The method of claim 1 , wherein the ligand comprises carboxymethyl-lycine-modified AGE.

11. The method of claim 1 , wherein the ligand comprises β-amyloid.

12. The method of claim 1 , wherein the ligand comprises calgranulin.

13. The method of claim 1 , wherein the ligand comprises S100b.

14. The method of claim 1 , wherein the ligand comprises amphoterin.

15. The method of claim 1 , wherein the compound of interest comprises a synthetic peptide.

16. The method of claim 1 , wherein the compound of interest comprises a peptidomimetic.

17. The method of claim 1 , wherein the compound of interest comprises an organic compound.

18. The method of claim 1 , wherein the compound of interest comprises an inorganic compound.

19. The method of claim 1 , wherein the compound of interest comprises a lipid.

20. The method of claim 1 , wherein the compound of interest comprises a carbohydrate.

21. The method of claim 1 , wherein the compound of interest comprises a nucleic acid.

22. A method for detection of RAGE ligands comprising:

adsorbing a RAGE ligand onto a solid surface;

adding a compound of interest and a protein comprising a RAGE fragment comprising the amino acid sequence SEQ ID NO: 3 to the preadsorbed ligand;

adding anti-RAGE antibody which binds to said protein and a secondary antibody which binds to the anti-RAGE antibody;

measuring the secondary antibody bound to the anti-RAGE antibody; and

comparing the amount of said protein bound to the ligand in the presence of varying amounts of the compound of interest.

23. The method of claim 22 , further comprising performing a colorimetric assay for the secondary antibody.

24. The method of claim 22 , wherein the anti-RAGE antibody and secondary antibody are allowed to complex prior to being added to the reaction.

25. The method of claim 22 , wherein the solid surface comprises a reaction vessel.

26. The method of claim 22 , wherein the solid surface comprises a dip-stick.

Assignments (8)
SECURITY INTEREST Recorded Sep 15, 2021
From: INTELLIGENT AUTOMATION, LLC
To: MADISON CAPITAL FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 057486/0906 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: TRANSTECH PHARMA, LLC
Reel/Frame 032621/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 031654/0878 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: TRANSTECH PHARMA, INC.
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0803 →
CONFIRMATION OF TERMINATION OF EXCLUSIVE PATENT LICENSE Recorded Jan 15, 2013
From: PFIZER, INC.
To: TRANSTECH PHARMA, INC.
Reel/Frame 029631/0111 →
CONFIRMATION OF TERMINATION OF EXCLUSIVE PATENT LICENSE Recorded Jul 2, 2010
From: PFIZER, INC.
To: TRANSTECH PHARMA, INC.
Reel/Frame 024694/0673 →
CONFIRMATION OF EXLCUSIVE PATENT LICENSE Recorded Feb 12, 2007
From: TRANSTECH PHARMA, INC.
To: PFIZER INC
Reel/Frame 018910/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2006
From: SHAHBAZ, MANOUCHEHR M.
To: TRANSTECH PHARMA, INC.
Reel/Frame 018226/0093 →